Literature DB >> 12014814

Treatment of heroin dependence with buprenorphine in primary care.

David A Fiellin1, Michael V Pantalon, Juliana P Pakes, Patrick G O'Connor, Marek Chawarski, Richard S Schottenfeld.   

Abstract

Buprenorphine is an effective treatment for heroin dependence. The feasibility and potential efficacy of buprenorphine with brief counseling in primary care is unknown. We enrolled 14 heroin dependent patients in a 13-week clinical trial using thrice weekly buprenorphine along with brief counseling in the primary care center of an urban medical center. Primary outcomes included urine toxicology and treatment retention. Opioid-positive urine toxicology tests reduced over the 13-week period from 95 to 25% (p < 0.05). Eleven patients (79%) had greater than or equal to one week of opioid-free urine toxicologies. Nine patients (64%) had greater than or equal to three weeks of opioid-free urine toxicologies. Eleven patients (79%) were retained through the maintenance phase. We conclude that buprenorphine maintenance is feasible in a primary care setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014814     DOI: 10.1081/ada-120002972

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  38 in total

1.  Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Authors:  Patrizia Amato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

Review 3.  Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment.

Authors:  Jennifer R Havens; Sharon L Walsh; P Todd Korthuis; David A Fiellin
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

4.  Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Authors:  Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham
Journal:  J Behav Health Serv Res       Date:  2017-07       Impact factor: 1.505

Review 5.  Prevention of HIV infection among injection drug users in resource-limited settings.

Authors:  David Vlahov; Angela M Robertson; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

6.  Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.

Authors:  P Todd Korthuis; Jessica Gregg; Wendy E Rogers; Dennis McCarty; Christina Nicolaidis; Joshua Boverman
Journal:  J Addict Med       Date:  2010-12       Impact factor: 3.702

7.  A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Scott E Provost; Zhen Huang; Petra Jacobs; Albert Hasson; Robert Lindblad; Hilary Smith Connery; Kristi Prather; Walter Ling
Journal:  Contemp Clin Trials       Date:  2010-01-29       Impact factor: 2.226

8.  Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Authors:  T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

9.  Integrating buprenorphine treatment into office-based practice: a qualitative study.

Authors:  Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

Review 10.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.